JEFFREY PORT, MD
While practicing thoracic surgery and teaching at Weill Cornell Medical Center, Jeffrey founded and chaired two companies:
RF Surgical Systems, which is focused on the detection and prevention of retained surgical items (sponge, gauze, or towel) during surgery, was purchased by Medtronic in 2015 for $235 million.
Angiocrine Bioscience, which creates cellular therapies designed to drive stem cell renewal in a variety of diseases.
Jeffrey earned his medical degree and finished his general surgery residency at New York University School of Medicine before completing surgical training at Weill Cornell and Memorial Sloan Kettering Cancer Center. He has published extensively on both immunotherapy treatment for lung and esophageal cancer and vaccine development.